The Question That Arrives After Diagnosis
Most families receive the same roadmap after a glioblastoma diagnosis: surgery if possible, followed by radiation and chemotherapy, then additional chemotherapy cycles. The standard drug is temozolomide, or TMZ. This approach has been standard since 2005.
But within days of diagnosis, many patients ask something more direct.
"Will this chemotherapy actually work on my tumor?"
It's a reasonable question. Glioblastoma is not a single disease. Each tumor has its own genetic fingerprint. Some respond well to standard chemotherapy. Others have built-in resistance mechanisms that can prevent treatment from working. Drug sensitivity analysis helps answer that question before chemotherapy starts.
Why Standard Protocol Applies One Answer to Many Tumors
Standard glioblastoma treatment uses the same chemotherapy approach for almost every patient. This approach has strong clinical evidence supporting it. But it was built on population-level data: what works for most people on average, not what works for any single patient's tumor.
The most commonly tested marker before chemotherapy is MGMT. The MGMT gene produces a DNA repair protein. When the MGMT promoter is methylated (chemically silenced), the protein is suppressed. Tumors with MGMT methylation usually respond better to temozolomide. Tumors without methylation can repair the DNA damage that TMZ causes, making the drug less effective.
MGMT testing matters. But it only captures part of tumor biology. Even patients with the same MGMT status respond to TMZ very differently.
Why Tumor Biology Varies So Widely
No two glioblastomas are genetically identical. Researchers studying patient-derived glioblastoma cells found major differences in how individual tumors respond to the same drugs. One study in Neuro-Oncology documented large differences in drug sensitivity among newly diagnosed glioblastoma samples. Even tumors that looked similar by standard markers showed very different responses to the same drugs.
A drug that works well in average trial data may work poorly against one specific tumor. The opposite can also be true. A drug with average results may work very well against a tumor with a particular genetic weakness.
Glioblastoma also changes over time. Different areas of the same tumor can have different mutations. Tumor cells can turn on multiple resistance pathways at once. Understanding these changes before treatment starts can help shape a better initial plan and support decisions later if the disease comes back.
What Drug Sensitivity Analysis Actually Measures
Drug sensitivity analysis goes beyond finding out whether a gene is mutated. It asks a direct question: when cells from your tumor are exposed to a specific drug, do they die?
Functional drug sensitivity testing uses tumor cells taken from tissue removed during surgery to test how those cells respond to drugs. The cells are exposed to multiple chemotherapy agents at different doses. Scientists measure cell death, apoptosis, or growth slowing. This creates a sensitivity profile specific to the patient's tumor.
Research on gene expression changes and drug sensitivity patterns in newly diagnosed and recurrent glioblastoma shows that drug responses differ between patients. These differences matter for treatment planning.
Molecular profiling takes a different approach. Instead of directly testing drug response, it maps the mutations, amplifications, deletions, and gene expression patterns that control how a tumor behaves. Whole exome sequencing (WES) reads nearly every protein-coding gene in the tumor. RNA sequencing shows which genes are turned on. Together, they give a clearer picture of the tumor's biology than any single test.
One pilot study found that whole exome sequencing identified drug combinations that were significantly more effective at reducing tumor size than standard single-drug approaches. Some patients had pathways that could be targeted, including PI3K/AKT/mTOR changes, that standard tests had missed.
What Standard Molecular Reports Often Miss
MGMT methylation and IDH status are important starting points. But they only show part of the picture. Standard pathology reports typically don't include:
- EGFR amplification subtypes, including EGFRvIII, which can affect eligibility for targeted drugs and clinical trials
- PTEN loss, which drives resistance to multiple drugs and activates the PI3K pathway
- CDK4 or CDK6 amplification relevant to cell cycle therapy
- RNA expression signatures showing tumor cell type and stem-cell-like features
- Drug pump overexpression, which can reduce how much drug reaches the tumor
- DNA damage response pathway mutations beyond MGMT
A study of a large glioblastoma group found that tumors have multiple changes that could be targeted beyond what standard tests find. Many would be missed by routine pathology.
A clinical review also showed that recommended testing panels vary widely in what they include. Extended testing often finds information useful for treatment choices.
For more about which molecular tests your tumor may need at diagnosis, see: What Molecular Tests Does Your Newly Diagnosed Glioblastoma Actually Need — and Why Your Tumor's Genetic Profile Determines Your Treatment Plan.
How Pre-Treatment Analysis May Support Treatment Decisions
It's important to understand what drug sensitivity analysis can and can't do. It doesn't replace your oncologist's judgment. It doesn't account for your overall health, how well you're doing physically, surgery results, or imaging findings. No single molecular test should decide a treatment plan.
What it can do is provide biological information your care team can use when making decisions. This might include:
- Confirming whether your tumor is likely to respond to standard temozolomide chemotherapy
- Identifying other drugs your tumor might respond to if the first treatment doesn't work
- Spotting possible resistance mechanisms before they show up on imaging
- Providing information for discussions about other drugs or clinical trial options
- Supporting decisions about drug combinations based on your tumor's biology
Many families pursue broader molecular testing not to replace their care team, but to have more information for those conversations. The goal is to make better decisions based on understanding your tumor's specific biology, not just what works on average.
For more on how drug sensitivity analysis connects to off-label medications, see: Repurposed Drugs and Drug Sensitivity Analysis for Glioblastoma: How Tumor Testing Identifies Off-Label Medications Beyond Standard Chemotherapy.
When Pre-Treatment Analysis Is Most Useful
Drug sensitivity analysis works best when done on fresh tissue from the initial surgery. This tissue is active and works well for testing how cells respond to drugs outside the body.
If fresh tissue is no longer available, comprehensive molecular testing of stored tumor blocks can still provide useful genetic and expression data. Next-generation sequencing, including WES and RNA sequencing, works on stored tissue.
Patients at the pre-treatment stage, reviewing their plan before starting radiation and chemotherapy, are in the best position to use this information. It's also worth doing for patients whose standard tests gave limited or unclear results.
What International Patients Need to Know
Many patients diagnosed in the United Kingdom, United States, Australia, Canada, Germany, France, the UAE, and New Zealand seek expert review after diagnosis. Families in London, Manchester, Birmingham, New York, Sydney, Melbourne, Toronto, Berlin, and Dubai regularly get precision oncology review alongside their regular care.
You don't need to be near an expert to get this help. Pathology reports, MRI files, surgical notes, and existing test results can be sent online. Initial consultations happen online. A family in Sydney or Dubai can get expert review of their tumor's biology without traveling.
One caregiver in Manchester described the experience: "We received the standard report from our oncologist, but we wanted to understand whether there was more information in the tumor itself. Having a fuller molecular picture helped us ask better questions at our next appointment."
Understanding your tumor's specific biology, not just what works on average, helps families make better informed decisions.
Common Mistakes Families Make After Diagnosis
- Assuming the standard pathology report is complete. The initial report is a starting point, not a complete look at tumor biology. Most reports test only a few markers.
- Waiting until recurrence to pursue deeper testing. Pre-treatment testing is usually more helpful than testing after the disease comes back, when options are fewer.
- Not gathering all relevant reports. Treatment discussions improve with all the information: pathology, imaging, surgical notes, and existing test results.
- Treating population statistics as personal predictions. Median survival numbers describe groups of patients, not what will happen to one person with a specific tumor.
- Not seeking expert interpretation of test results. Even when testing is done, understanding what it means for treatment requires specialist knowledge that general oncology doesn't always provide.
Questions to Ask Your Oncology Team
- What molecular markers have been tested on my tumor?
- Has MGMT promoter methylation been checked? What was the result?
- Is there tissue from surgery left that could be tested further?
- Has my tumor been tested for EGFR amplification or EGFRvIII?
- Are there any pathways in my tumor's genetic profile that can be targeted?
- Would more molecular testing change the recommended treatment?
- Is there a clinical trial that my tumor's genetics might make me eligible for?
What Reports Should You Gather Before Seeking an Expert Review?
If you're thinking about getting expert review of your case, these documents are most useful:
- Pathology Report – the written diagnosis from the neuropathologist, including tumor grade and WHO classification
- Histopathology Report – including any immunohistochemistry results
- MRI Brain Reports and Imaging Files – scans before and after surgery, in DICOM format if possible
- Surgical Notes – details about how much tumor was removed and any findings during surgery
- Molecular Testing Results – any existing MGMT, IDH, EGFR, or next-generation sequencing results
- Current Treatment Plan – the full chemoradiation or chemotherapy protocol your oncology team recommended
- Previous Treatment History – if you've had any prior treatment
Having these documents ready means expert review can start without waiting. For a complete checklist, see: Preparing for Your Tumor Intelligence Review: The Complete Checklist of Reports, Scans, and Data Your Expert Team Needs.
Every glioblastoma is different biologically. A careful review of your pathology and imaging might reveal insights worth discussing with your care team. Many families want more clarity before making major treatment decisions. They aren't trying to replace their oncologist, just to go into those conversations better informed. International patients often start with an online consultation and report review. Specialized expertise isn't limited by where you live.
When to Talk to Your Doctor
Talk to your oncologist about drug sensitivity analysis or broader molecular testing if:
- Your initial pathology report tested only a few molecular markers
- Your MGMT status was unmethylated or unclear
- You're thinking about a clinical trial before starting standard treatment
- You want a second opinion on whether your tumor's genetics could support other or additional treatment options
- You want a clearer picture of your tumor's biology before deciding on a treatment plan
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.